Salcedo Luis F, LeBlanc Brooke L, Martin Sarah M, Nossaman Bobby D
Department of Anesthesiology, Ochsner Clinic Foundation, New Orleans, LA.
The University of Queensland Faculty of Medicine, Ochsner Clinical School, New Orleans, LA.
Ochsner J. 2021 Fall;21(3):240-244. doi: 10.31486/toj.20.0101.
Postoperative wound pain is commonly observed in the pediatric postanesthesia care unit (PACU) following tonsillectomy, adenoidectomy, and adenotonsillectomy (adeno/tonsillectomy), which contributes to increased medical care costs and delayed facility discharge. The purpose of this study was to review the benefits of preoperative administration of Hycet elixir (2.5 mg hydrocodone and 108 mg acetaminophen per 5 mL) in a pediatric population aged 1 to 9 years following adeno/tonsillectomy. Patient demographics, comorbidities, surgical and anesthetic times, need for postoperative rescue therapies, and PACU recovery and length of stay times were measured in pediatric patients who received preoperative administration of Hycet elixir (0.2 mg/kg hydrocodone) for adeno/tonsillectomy in an outpatient setting compared to a control group. The Hycet elixir group had significant reductions in PACU and hospital lengths of stay and significant reductions in the need for postoperative rescue analgesics. No significant differences were observed in emergence times or in the incidences of unplanned hospital admission between the control and Hycet elixir groups. These data show that the preoperative administration of Hycet elixir is well tolerated in the pediatric patient population undergoing adeno/tonsillectomy and appears to significantly reduce the need for postoperative rescue analgesics and postoperative care times. These data support the use of preoperative administration of Hycet elixir in this patient population.
扁桃体切除术、腺样体切除术及腺扁桃体切除术(腺/扁桃体切除术)后,小儿麻醉后护理单元(PACU)中常见术后伤口疼痛,这会导致医疗费用增加和出院延迟。本研究的目的是回顾术前给予海赛特酏剂(每5毫升含2.5毫克氢可酮和108毫克对乙酰氨基酚)对1至9岁接受腺/扁桃体切除术的儿科患者的益处。在门诊环境中,对接受术前给予海赛特酏剂(0.2毫克/千克氢可酮)进行腺/扁桃体切除术的儿科患者,与对照组相比,测量患者人口统计学、合并症、手术和麻醉时间、术后抢救治疗需求以及PACU恢复和住院时间。海赛特酏剂组的PACU和住院时间显著缩短,术后抢救镇痛药的需求也显著减少。对照组和海赛特酏剂组在苏醒时间或非计划住院发生率方面未观察到显著差异。这些数据表明,术前给予海赛特酏剂在接受腺/扁桃体切除术的儿科患者中耐受性良好,并且似乎显著减少了术后抢救镇痛药的需求和术后护理时间。这些数据支持在该患者群体中使用术前给予海赛特酏剂。